• 1
    Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 94087.
  • 2
    Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55(Suppl. 1): i1635.
  • 3
    Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically-guided dosing. Clin Pharmacokinet 2007; 46: 187208.
  • 4
    Bloomfeld RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003; 17: 6973.
  • 5
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 48797.
  • 6
    Lopez-Sanroman A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24(Suppl. 3): 459.
  • 7
    DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 2009.
  • 8
    Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med 2001; 134: 10046.
  • 9
    Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized placebo-controlled trial. Ann Intern Med 1996; 124: 20411.
  • 10
    Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001; 7: 23742.
  • 11
    Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005; 11: 4217.
  • 12
    Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 292933.
    Direct Link:
  • 13
    Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 14
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1918.
  • 15
    Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 6675.
  • 16
    Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 57785.
  • 17
    Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn’s disease. Aliment Pharmacol Ther 2006; 24: 1099103.
  • 18
    Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 153544.
    Direct Link:
  • 19
    Lopez San Roman A, Bermejo F, Carrera E, et al. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 24957.
  • 20
    Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 173342.
    Direct Link:
  • 21
    Robinson A, Bokemeyer B, Cripps S, et al. Towards better patient compliance in IBD: report of an international compliance consensus meeting. Gastroenterol Hepatol 2005; 1: 20615.
  • 22
    Mantzaris GJ, Roussos A, Kalantzis C, et al. How adherent to treatment with azathioprine are patients with Crohn’s disease in long-term remission? Inflamm Bowel Dis 2007; 13: 44650.
  • 23
    Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; Apr 16; [Epub ahead of print].
    Direct Link:
  • 24
    Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134: 96877.
  • 25
    Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 2006; 55(Suppl. 1): i115.
  • 26
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 41729.
  • 27
    Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl. A): 536.
  • 28
    Kroplin T, Weyer N, Gutsche S, et al. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998; 54: 26571.
  • 29
    Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 42936.
  • 30
    Dilger K, Schaeffeler E, Lukas M, et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn’s disease during 1 year of treatment with azathioprine or mesalazine. Ther Drug Monit 2007; 29: 15.
  • 31
    Herrlinger KR, Fellermann K, Fischer C, et al. Thioguanine-nucleotides do not predict efficacy of thioguanine in Crohn’s disease. Aliment Pharmacol Ther 2004; 19: 126976.
  • 32
    Neurath MF, Kiesslich R, Teichgraber U, et al. 6-Thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn’s disease. Clin Gastroenterol Hepatol 2005; 3: 100714.
  • 33
    Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 11238.
  • 34
    Maneesriwongul WL, Tulathong S, Fennie KP, et al. Adherence to antiretroviral medication among HIV-positive patients in Thailand. J Acquir Immune Defic Syndr 2006; 43(Suppl. 1): S11922.
  • 35
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 43944.
  • 36
    Sandborn WJ. Rational dosing of azathioprine and mercaptopurine. Gut 2001; 48: 5912.
  • 37
    Cuffari C, Theoret Y, Latour S, et al. Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996; 39: 4016.
  • 38
    Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001; 32: 668.
  • 39
    Riley SA, Mani V, Goodman MJ, et al. Why do patients with ulcerative colitis relapse? Gut 1990; 31: 17983.
  • 40
    Mackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 100612.
  • 41
    Oliva-Hemker MM, Abadom V, Cuffari C, et al. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr 2007; 44: 1804.
  • 42
    Mawdsley JE, Irving PM, Makins RJ, et al. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol 2006; 18: 24953.
  • 43
    Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2: 37988.
  • 44
    Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 104753.
  • 45
    Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005; 22: 116.
  • 46
    Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 66570.
  • 47
    Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36: 716.
  • 48
    Reuther LO, Sonne J, Larsen NE, et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol 2003; 38: 9727.
  • 49
    Wusk B, Kullak-Ublick GA, Rammert C, et al. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004; 16: 140713.
  • 50
    Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine therapy in inflammatory bowel disease. Gut 2006; 55: 142331.
  • 51
    Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 18128.
  • 52
    Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 53849.